DE69939269D1 - Verfahren zur bestimmung der suzeptibilität zur sepsisentwicklung und arzneimittel zur behandlung von sepsis - Google Patents

Verfahren zur bestimmung der suzeptibilität zur sepsisentwicklung und arzneimittel zur behandlung von sepsis

Info

Publication number
DE69939269D1
DE69939269D1 DE69939269T DE69939269T DE69939269D1 DE 69939269 D1 DE69939269 D1 DE 69939269D1 DE 69939269 T DE69939269 T DE 69939269T DE 69939269 T DE69939269 T DE 69939269T DE 69939269 D1 DE69939269 D1 DE 69939269D1
Authority
DE
Germany
Prior art keywords
sepsis
sezeptibility
medicaments
determining
development
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69939269T
Other languages
German (de)
English (en)
Inventor
Giovine Francesco S Di
Gordon W Duff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Interleukin Genetics Inc
Original Assignee
Interleukin Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Interleukin Genetics Inc filed Critical Interleukin Genetics Inc
Application granted granted Critical
Publication of DE69939269D1 publication Critical patent/DE69939269D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/131—Allele specific probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69939269T 1998-10-30 1999-11-01 Verfahren zur bestimmung der suzeptibilität zur sepsisentwicklung und arzneimittel zur behandlung von sepsis Expired - Lifetime DE69939269D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/183,850 US6251598B1 (en) 1998-10-30 1998-10-30 Methods for diagnosing sepsis
PCT/US1999/025633 WO2000037679A2 (en) 1998-10-30 1999-11-01 Method for determining the susceptibility to developing sepsis and therapeutics for the treatment of sepsis

Publications (1)

Publication Number Publication Date
DE69939269D1 true DE69939269D1 (de) 2008-09-18

Family

ID=22674558

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69939269T Expired - Lifetime DE69939269D1 (de) 1998-10-30 1999-11-01 Verfahren zur bestimmung der suzeptibilität zur sepsisentwicklung und arzneimittel zur behandlung von sepsis

Country Status (10)

Country Link
US (2) US6251598B1 (enExample)
EP (1) EP1127168B1 (enExample)
JP (1) JP2002533096A (enExample)
AT (1) ATE403745T1 (enExample)
AU (1) AU779772B2 (enExample)
CA (1) CA2346960A1 (enExample)
DE (1) DE69939269D1 (enExample)
ES (1) ES2308861T3 (enExample)
IL (1) IL142438A0 (enExample)
WO (1) WO2000037679A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711040D0 (en) * 1997-05-29 1997-07-23 Duff Gordon W Prediction of inflammatory disease
US20050032077A1 (en) * 1998-03-10 2005-02-10 Duff Gordon W. Detecting genetic predisposition to sight-threatening diabetic retinopathy
US6251598B1 (en) * 1998-10-30 2001-06-26 Interleukin Genetics, Inc. Methods for diagnosing sepsis
WO2002024951A1 (en) * 2000-09-20 2002-03-28 Genaissance Pharmaceuticals, Inc. Haplotypes of the il1b gene
US20040028651A1 (en) * 2001-03-29 2004-02-12 Karrupiah Muthumani Composition and methods of using hiv vpr
WO2003030827A2 (en) * 2001-10-05 2003-04-17 The Trustees Of The University Of Pennsylvania Compositions for and methods of treating and preventing sirs/sepsis
US20080311581A1 (en) * 2001-11-19 2008-12-18 David Wyllie Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases
AU2002359431A1 (en) * 2001-11-19 2003-06-10 Interleukin Genetics, Inc. Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases
US7645573B2 (en) * 2002-11-12 2010-01-12 Becton, Dickinson And Company Diagnosis of sepsis or SIRS using biomarker profiles
US20040157242A1 (en) * 2002-11-12 2004-08-12 Becton, Dickinson And Company Diagnosis of sepsis or SIRS using biomarker profiles
JP2006515670A (ja) * 2002-11-12 2006-06-01 ベクトン，ディッキンソン アンド カンパニー バイオマーカープロファイルを用いる敗血症またはｓｉｒｓの診断
WO2005038427A2 (en) * 2003-06-05 2005-04-28 Medical Gene Center Ltd. Rapid identification of viruses of the upper respiratory tract infection including sars causing coronus viruses
PL1673472T3 (pl) * 2003-10-06 2011-07-29 Novartis Ag Zastosowanie polimorfizmów genetycznych do przewidywania hepatotoksyczności indukowanej przez leki
AU2005219473A1 (en) * 2004-03-04 2005-09-15 The University Of British Columbia Toll-like receptor 2 (TLR-2) haplotypes predict outcome of patients
WO2005085273A1 (en) * 2004-03-04 2005-09-15 The University Of British Columbia Thrombomodulin (thbd) haplotypes predict outcome of patients
US8034553B2 (en) * 2004-06-24 2011-10-11 Kimberly-Clark Worldwide, Inc. Biomarkers for wound healing
US20060157647A1 (en) * 2005-01-18 2006-07-20 Becton, Dickinson And Company Multidimensional liquid chromatography/spectrometry
EP1851245B1 (en) 2005-01-26 2012-10-10 Amgen Fremont Inc. Antibodies against interleukin-1 beta
RU2286154C2 (ru) * 2005-02-17 2006-10-27 Владимир Алексеевич Шатров Способ лечения воспалительных заболеваний головного мозга
US8293521B2 (en) 2005-03-30 2012-10-23 Shimadzu Corporation Method of dispensing nonvolatile liquid in reaction vessel and reaction vessel processing apparatus
JP2008538007A (ja) 2005-04-15 2008-10-02 ベクトン，ディッキンソン アンド カンパニー 敗血症の診断
US8669113B2 (en) 2008-04-03 2014-03-11 Becton, Dickinson And Company Advanced detection of sepsis
EP2382235B1 (en) * 2008-12-19 2016-02-24 Christiane Hilger Novel caviidae allergen and uses thereof
EP2676675B1 (en) 2011-02-18 2019-04-10 Stemdr Inc. Composition containing inducer of sirt1 expression for preventing or treating sepsis or septic shock
US10126305B2 (en) 2013-06-25 2018-11-13 University of Pittsburg—Of the Commonwealth System of Higher Education Proteomic biomarkers of sepsis in elderly patients
JP2019503176A (ja) 2016-01-12 2019-02-07 インターロイキン ジェネティクス， インコーポレイテッド 処置に対する応答を予測するための方法
US10329620B2 (en) 2017-01-12 2019-06-25 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease
CA3142662A1 (en) 2019-06-06 2020-12-10 Sitokine Limited Compositions and methods for treating lung, colorectal and breast cancer
WO2021028469A1 (en) 2019-08-12 2021-02-18 Sitokine Limited Compositions and methods for treating cytokine release syndrome and neurotoxicity
WO2021205013A1 (en) 2020-04-09 2021-10-14 Sitokine Limited Compositions and methods for treating covid-19

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
WO1991017249A1 (en) 1990-05-01 1991-11-14 Cetus Corporation Interleukin-1 antagonist and uses thereof
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
DE4408890A1 (de) 1994-03-16 1995-09-21 Knoll Ag Verwendung von Il-1-Antagonisten als Arzneimittel zur Behandlung von Erkrankungen mit einem erhöhten Interleukin-6 Serumspiegel
US5686246A (en) 1995-08-03 1997-11-11 Kornman; Kenneth S. Detecting genetic predisposition to periodontal disease
US5942390A (en) * 1996-01-12 1999-08-24 Cedars-Sinai Medical Center Method of diagnosing predisposition for ulcerative colitis in Jewish population by detection of interleukin-1 receptor antagonist polymorphism
WO1997034616A1 (en) 1996-03-18 1997-09-25 Medical Science Systems, Inc. A method for periodontal disease treatment
GB9621129D0 (en) 1996-10-10 1996-11-27 Duff Gordon W Detecting genetic predisposition to sight-threatening diabetic retinopathy
US6210877B1 (en) 1997-03-10 2001-04-03 Interleukin Genetics, Inc. Prediction of coronary artery disease
GB9711040D0 (en) 1997-05-29 1997-07-23 Duff Gordon W Prediction of inflammatory disease
AU760856B2 (en) 1997-05-29 2003-05-22 Interleukin Genetics, Inc. Diagnostics and therapeutics for chronic obstructive airway disease
US6251598B1 (en) * 1998-10-30 2001-06-26 Interleukin Genetics, Inc. Methods for diagnosing sepsis

Also Published As

Publication number Publication date
AU3995600A (en) 2000-07-12
WO2000037679A3 (en) 2001-01-11
EP1127168B1 (en) 2008-08-06
US6551785B2 (en) 2003-04-22
US6251598B1 (en) 2001-06-26
AU779772B2 (en) 2005-02-10
EP1127168A2 (en) 2001-08-29
US20010034032A1 (en) 2001-10-25
WO2000037679A2 (en) 2000-06-29
ATE403745T1 (de) 2008-08-15
CA2346960A1 (en) 2000-06-29
ES2308861T3 (es) 2008-12-01
IL142438A0 (en) 2002-03-10
JP2002533096A (ja) 2002-10-08

Similar Documents

Publication Publication Date Title
DE69939269D1 (de) Verfahren zur bestimmung der suzeptibilität zur sepsisentwicklung und arzneimittel zur behandlung von sepsis
DE69430231D1 (de) Biosensor zum Messen der Alkoholkonzentration, Verfahren zur Herstellung des Biosensors, und den Biosensor benutzendes Betrunkenheitsmessgerät
NO973444D0 (no) Fremgangsmåter og forbindelser for magnetrelaksometrisk påvisning av analytter, samt anvendelse av slike
IT1079695B (it) Reattivo di elevata specificita' e sensibilita' per la determinazione quantitativa di composti in tracce in mezzi di vario genere
ATE244018T1 (de) Herstellungb und verwendung eines spezifischen gaba-aalpha5 rezeptorligands zur behandlung der erkrankung von alzheimer
DE69739000D1 (de) Gerät und verfahren zur bestimmung der quelle eines lokalsignals
DE59400669D1 (de) Verfahren zur nasschemischen Behandlung von Werkstücken
DE3575517D1 (de) Verfahren zur voraussage und feststellung des eintritts der ovulation.
DE69634951D1 (de) Topische verwendung von betulinsäure zur behandlung bösartiger melanome
DE69019795D1 (de) Verfahren zur Feststellung der Empfindlichkeit von HIV-1 für Zidovudine und dazu geeignete Oligonukleotide.
DE69626311D1 (de) Zusammensetzung zur behandlung von wäsche sowie verfahren hierfür
DE69416645D1 (de) Verfahren zur Behandlung von photographischem Abwasser
DE69524919D1 (de) Verfahren und Vorrichtung zur Bestimmung der Konzentration von Gaskomponenten
DE69627770D1 (de) Verfahren zum Bestimmen der Gesamtchlormenge und Kit dafür
AT360661B (de) Verfahren zur bestimmung von prothrombin und reagens zur durchfuehrung des verfahrens
DE69504949T3 (de) Verwendung eines Antagonisten der Substanz P zur Behandlung von Hautrötungen neurogen Ursprungs
DE69824775D1 (de) Verfahren zur Behandlung von Chromoxid enthaltenden Substanzen in grossen Mengen
DE69704328D1 (de) Verfahren zur quantitativen Bestimmung von 1,5-Anhydroglucitol, sowie Reagenz zur quantitativen Bestimmung
DE69937678D1 (de) Verfahren zur schnellen bestimmung von bakterien
ATE371453T1 (de) Verfahren zur behandlung von okularen neovaskularen erkrankungen
DE69934789D1 (de) Verfahren zur bestimmung der antibiotikasensitivität von bakterien
DE69607559D1 (de) Verfahren zur Behandlung von Phenolteer
DE59814359D1 (de) Mikrostrukturierter biosensor, verwendung des biosensors und verfahren zur immobilisierung von biokatalysatoren
DE69524479D1 (de) Verfahren zur Behandlung von sauren Abgasen
DE69930725D1 (de) Verfahren und kits zur behandlung von vulvovaginalen candidosen mit mikonazolnitrat

Legal Events

Date Code Title Description
8364 No opposition during term of opposition